Key result
ICDs remain the primary treatment to prevent SCD in Brugada syndrome after careful risk stratification.
Why the study?
Brugada syndrome remains a major diagnostic and therapeutic challenge, especially in asymptomatic patients and in risk stratification.
This comprehensive review highlights the evolving understanding of Brugada syndrome's complex genetic basis, diagnostic criteria, and the emerging role of epicardial ablation alongside traditional ICD therapy for preventing sudden cardiac death.
Emphasizes cautious risk stratification in Brugada syndrome; leaves open optimal genetic testing and ablation strategies pending prospective data.
Brugada syndrome is a rare inherited cardiac arrhythmia disorder characterized by a high risk of sudden cardiac death in structurally normal hearts. This channelopathy is associated with syncope caused by ventricular tachyarrhythmias, especially among the male population. Current studies results show that this illness is not solely inherited in an autosomal dominant manner, which occurs in only 3 out of 10 patients. Intensive research has deepened the understanding of its genetic, electrophysiological and clinical aspects. However, Brugada syndrome remains a major diagnostic and therapeutic challenge, especially in asymptomatic patients and in risk stratification. The main type of treatment remains implantable cardioverter-defibrillator, but results of clinical studies show that epicardial ablation can also represent satisfactory results. This review provides a summarized synthesis of current knowledge on Brugada syndrome, including epidemiology, pathophysiology, genetic basis, clinical presentation, electrocardiographic characteristics and diagnostic criteria, risk stratification, treatment approaches and preventive measures in a comprehensive and detailed way.
No takes yet. Share an insight, caveat, or question.
Krawczyk et al. (2026) conducted a review in Brugada syndrome. Brugada syndrome is a rare inherited channelopathy requiring careful risk stratification, with implantable cardioverter-defibrillators remaining the primary treatment to prevent sudden cardiac death.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: